Liu Jiali, Song Xiaowen, Song Xinni, Fu Xinyue, Niu Shufang, Chang Hong, Shi Songli, Yang Meiqing, Zhao Ruiqi, Wang Peng, Qi Jun, Bai Wanfu
Department of Pharmacy, Baotou Medical College, Baotou, China.
The Second Affiliated Hospital of Baotou Medical College, Baotou, China.
Front Mol Biosci. 2025 Aug 29;12:1607103. doi: 10.3389/fmolb.2025.1607103. eCollection 2025.
Hepatic Fibrosis (HF), a pathological remodeling process triggered by persistent liver damage, is marked by the excessive buildup of extracellular matrix (ECM), leading to a gradual deterioration of liver function and an increased likelihood of advancing to cirrhosis and liver failure.
This study adopts a systematic pharmacology methodology, initially employing bibliometric analysis to identify traditional Chinese medicine (TCM) formulations and individual herbs with potential anti-HF properties. Subsequently, a multi-dimensional network analysis is conducted to pinpoint core active components. Experimental investigations involve the construction of a carbon tetrachloride (CCl)-induced rat model of liver fibrosis, complemented by transcriptomic technology to systematically elucidate the mechanisms of action of the active components in TCM.
In this study, kaempferol (KA), identified as the principal active compound with anti-fibrotic properties, was selected from traditional Chinese medicine (TCM) and TCM prescriptions through a combination of bibliometric analysis and network pharmacology. Pharmacodynamic evaluations, including pathological section analyses, demonstrated that KA effectively mitigated the fibrotic process and decreased collagen deposition. Further corroborated by ELISA experiments, kaempferol exhibited pronounced anti-fibrotic effects, inhibited inflammatory responses, restored liver function indices, and ameliorated the progression of liver fibrosis. Mechanistic investigations revealed that KA modulated fatty acid metabolism, retinol metabolism, and arachidonic acid metabolism by regulating the expression of key metabolic enzyme genes such as and , and significantly influenced the activity of the PPAR signaling pathway. Additionally, it impacted the dysregulation of lipid metabolism and inflammatory response pathways, significantly inhibited hepatic stellate cell (HSC) activation, and reduced ECM accumulation.
This finding elucidates the mechanism by which KA attenuates HF through multi-target regulation, and provides a theoretical basis for metabolic reprogramming-based therapeutic strategies with translational valu.
肝纤维化(HF)是一种由持续性肝损伤引发的病理重塑过程,其特征是细胞外基质(ECM)过度积聚,导致肝功能逐渐恶化,并增加发展为肝硬化和肝衰竭的可能性。
本研究采用系统药理学方法,首先运用文献计量分析来识别具有潜在抗肝纤维化特性的中药配方和单味草药。随后进行多维度网络分析以确定核心活性成分。实验研究包括构建四氯化碳(CCl)诱导的大鼠肝纤维化模型,并辅以转录组技术来系统阐明中药活性成分的作用机制。
在本研究中,通过文献计量分析和网络药理学相结合的方法,从中药及其方剂中筛选出具有抗纤维化特性的主要活性化合物山奈酚(KA)。包括病理切片分析在内的药效学评价表明,KA有效减轻了纤维化过程并减少了胶原沉积。ELISA实验进一步证实,山奈酚具有显著的抗纤维化作用,抑制炎症反应,恢复肝功能指标,并改善肝纤维化进程。机制研究表明,KA通过调节关键代谢酶基因如 和 的表达来调节脂肪酸代谢、视黄醇代谢和花生四烯酸代谢,并显著影响PPAR信号通路的活性。此外,它影响脂质代谢和炎症反应通路的失调,显著抑制肝星状细胞(HSC)活化,并减少ECM积累。
这一发现阐明了KA通过多靶点调节减轻肝纤维化的机制,并为具有转化价值的基于代谢重编程的治疗策略提供了理论依据。